Cargando…

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) are established oncogenic drivers of NSCLC. A mutation that results in loss of exon 14...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drusbosky, Leylah M., Dawar, Richa, Rodriguez, Estelamari, Ikpeazu, Chukwuemeka V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381548/ https://www.ncbi.nlm.nih.gov/pubmed/34425853 http://dx.doi.org/10.1186/s13045-021-01138-7

Ejemplares similares

Therapeutic strategies in RET gene rearranged non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer
por: Desai, Alisha, et al.
Publicado: (2022)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
por: Puri, Megha, et al.
Publicado: (2023)

EURISOL-DS METEX: Operation Manual for the METEX1-Exeriment in IPUL
por: E. Platacis, A. Zik (IPUL),F.Groeschel, S. Dementjev (PSI)
Publicado: (27/1)

CFD post analysis of METEX-tests
por: Laure Blumenfeld, Cyril Kharoua, Yacine Kadi, Karel Samec, Mats Lindroos (CERN)
Publicado: (30/0)

Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
por: Kareff, Samuel A., et al.
Publicado: (2023)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Non-small cell lung cancer with MET exon 14 skip mutation: case report
por: Clough, Wolfgang, et al.
Publicado: (2022)

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

EURISOL-DS METEX: CERN SAFETY COMMISSION RECOMMENDATIONS
por: J.Gulley (CERN: SC/GS)
Publicado: (27/1)

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2017)

EURISOL-DS METEX1: LDV measurement to detect Cavitations
por: Lettry, Jacques, et al.
Publicado: (27/1)

EURISOL-DS METEX: Cooling and Temperature Control of the Mercury Loop
por: Stefan Joray
Publicado: (27/1)

Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
por: Katakura, Seigo, et al.
Publicado: (2019)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
por: Pruis, Melinda A., et al.
Publicado: (2020)

MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
por: Socinski, Mark A., et al.
Publicado: (2021)

Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA
por: Gococo-Benore, Denise A, et al.
Publicado: (2022)

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
por: Choi, Wonyoung, et al.
Publicado: (2021)

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
por: Janzic, Urska, et al.
Publicado: (2023)

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
por: Blaquier, Juan Bautista, et al.
Publicado: (2022)

MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
por: Lung, Jrhau, et al.
Publicado: (2019)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
por: Zheng, Difan, et al.
Publicado: (2016)

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2021)

Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer
por: Song, Yaolin, et al.
Publicado: (2021)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
por: Nitta, Naohiro, et al.
Publicado: (2023)

Multiple exon skipping strategies to by-pass dystrophin mutations
por: Adkin, Carl F., et al.
Publicado: (2012)

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
por: Chen, Zhuxing, et al.
Publicado: (2021)

Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series
por: Ravindranathan, Deepak, et al.
Publicado: (2021)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
por: Kim, Tae Woo, et al.
Publicado: (2022)

The METEX study: Methotrexate versus expectant management in women with ectopic pregnancy: A randomised controlled trial
por: van Mello, Norah M, et al.
Publicado: (2008)

Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
por: Watari, Naokazu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1v1puf24asg6o2p2mqqis87ddb